Summary: In a small mechanistic randomized trial of 61 adults with obesity, once-daily oral semaglutide escalated to 50 mg lowered ad libitum energy intake by 39.2 percentage points versus placebo at week 20 (95% CI -59.0 to -19.4) and reduced body weight by 9.8% versus 1.5%. No significant change in gastric emptying was detected.
PICO Summary
| Element | Detail |
|---|---|
| Population | 61 adults living with obesity; double-blind, randomized, placebo-controlled clinical pharmacology trial (multi-site, Europe). |
| Intervention | Once-daily oral semaglutide, dose-escalated to 50 mg over 20 weeks (semaglutide arm within the randomized 61 participants). |
| Comparison | Matched once-daily oral placebo over 20 weeks (placebo arm within the randomized 61 participants). |
| Outcome | Primary endpoint, relative change from baseline in ad libitum energy intake at week 20: -39.2 percentage points (95% CI -59.0 to -19.4) versus placebo. Body weight: -9.8% with semaglutide versus -1.5% with placebo (no CI or p reported in abstract). Reduced hunger and increased fullness, satiety, and control of eating reported. Gastric emptying (paracetamol absorption): no statistically significant difference at week 20. ARR/NNT not applicable to these continuous endpoints. |
Oral semaglutide and appetite control
RCT · obesity · 20 weeks
High-dose oral semaglutide cut ad libitum energy intake by 39.2 percentage points versus placebo at 20 weeks and reduced body weight, with no change in gastric emptying, supporting a central satiety mechanism.
Expert Commentary
This is a mechanistic clinical pharmacology study, not an efficacy trial, and it should be read as such. The verdict is that high-dose oral semaglutide produces a clear, statistically robust reduction in ad libitum energy intake and a parallel drop in body weight over twenty weeks, with the appetite and control-of-eating signals pointing to a central, satiety-driven mechanism rather than gastric retention, since gastric emptying did not differ from placebo. The single limitation that most constrains interpretation is sample size: with only sixty-one participants randomized, the body-weight estimate is reported without confidence intervals or a p value in the abstract, and short-term intake measured at a research lunch may not track free-living eating. Sponsorship is also material here, as the study was funded by the manufacturer and most authors are company employees, which warrants cautious appraisal of an effect this large. Can I use this with my patients? Not directly, because this is a surrogate-outcome study in a small selected cohort, but it usefully reassures that the appetite benefit of the 50 mg oral dose is real and mechanistically plausible for patients with obesity already considering this therapy. Larger outcome trials should confirm whether these intake reductions translate into durable, clinically meaningful weight loss.
References
Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, Adrian CL. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes Obes Metab. 2024;26(10):4480-4489. doi:10.1111/dom.15802